Evidence map›Paper›PMID 39269189›Full record

ArticleAntimicrobial agents and chemotherapy2024

Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal

Shunsuke Numata, Takafumi Hara, Masaaki Izawa, Yosuke Okuno, Yasuhiko Sato, Shoji Yamane, Hideki Maki, Takafumi Sato, Yoshinori Yamano

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shunsuke NumataLaboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Toyonaka, Japan.ORCID 0009-0004-6585-2893
Takafumi HaraLaboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Toyonaka, Japan.
Masaaki IzawaLaboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Toyonaka, Japan.
Yosuke OkunoShionogi TechnoAdvance Research & Co., Ltd., Toyonaka, Japan.
Yasuhiko SatoBusiness Development Department, Shionogi & Co., Ltd., Toyonaka, Japan.
Shoji YamaneShionogi TechnoAdvance Research & Co., Ltd., Toyonaka, Japan.
Hideki MakiLaboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Toyonaka, Japan.
Takafumi SatoLaboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Toyonaka, Japan.
Yoshinori YamanoLaboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Toyonaka, Japan.

Funding

Shionogi (Shionogi & Co. Ltd.)
6 · The paper itself

Abstract

Treatment of

Indexed as

Antibodies, MonoclonalPseudomonas aeruginosaPseudomonas InfectionsAnimalsCrystallography, X-RayCytokinesHemolysisHumansLungMiceNeutrophilsPhagocytosisType III Secretion SystemsAntibodies, MonoclonalCytokinesType III Secretion Systemsanti-virulence therapymonoclonal antibodymouse infection modelPcrVPseudomonas aeruginosatype III secretion system

Identifiers

PMID39269189
PMCPMC11459929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.